Study S002325

The Role of Exenatide in Type 1 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00456300
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 11
Start: 2007-03
Primary completion: 2009-03
Lead sponsor: Montefiore Medical Center
Conditions: Type 1 Diabetes
Interventions: DRUG:Exenatide; DRUG:Insulin
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone [0-120 minutes post-dose]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026856	The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Raman VS, Diabetes care	2010	Randomized trial	PMID 20332358 DOI	cites ClinicalTrials.gov:NCT00456300; registry reference DERIVED:20332358